CN1684971A - 包括甾醇和 /或甾烷醇的新结构和组合物 ,以及特殊类别的抗炎药和其治疗或预防心血管病及其潜伏状况的用途 ,包括治疗高脂血症和其它以炎症为部分病因或症状的病症 - Google Patents

包括甾醇和 /或甾烷醇的新结构和组合物 ,以及特殊类别的抗炎药和其治疗或预防心血管病及其潜伏状况的用途 ,包括治疗高脂血症和其它以炎症为部分病因或症状的病症 Download PDF

Info

Publication number
CN1684971A
CN1684971A CNA038230283A CN03823028A CN1684971A CN 1684971 A CN1684971 A CN 1684971A CN A038230283 A CNA038230283 A CN A038230283A CN 03823028 A CN03823028 A CN 03823028A CN 1684971 A CN1684971 A CN 1684971A
Authority
CN
China
Prior art keywords
compound
stanols
acid
sterol
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038230283A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·P·库特奈伊
P·海登·普里查德
丁阳兵
基肖尔·M·瓦桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forbes Medi-Tech Inc
Original Assignee
Forbes Medi-Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/255,558 external-priority patent/US20040236125A1/en
Application filed by Forbes Medi-Tech Inc filed Critical Forbes Medi-Tech Inc
Publication of CN1684971A publication Critical patent/CN1684971A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA038230283A 2002-09-25 2003-09-25 包括甾醇和 /或甾烷醇的新结构和组合物 ,以及特殊类别的抗炎药和其治疗或预防心血管病及其潜伏状况的用途 ,包括治疗高脂血症和其它以炎症为部分病因或症状的病症 Pending CN1684971A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/255,558 2002-09-25
US10/255,558 US20040236125A1 (en) 2002-09-25 2002-09-25 Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
US66484303A 2003-09-16 2003-09-16
US10/664,843 2003-09-16

Publications (1)

Publication Number Publication Date
CN1684971A true CN1684971A (zh) 2005-10-19

Family

ID=32044971

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038230283A Pending CN1684971A (zh) 2002-09-25 2003-09-25 包括甾醇和 /或甾烷醇的新结构和组合物 ,以及特殊类别的抗炎药和其治疗或预防心血管病及其潜伏状况的用途 ,包括治疗高脂血症和其它以炎症为部分病因或症状的病症

Country Status (10)

Country Link
EP (1) EP1556406A1 (ja)
JP (1) JP2006503840A (ja)
KR (1) KR20050084572A (ja)
CN (1) CN1684971A (ja)
AU (1) AU2003266885A1 (ja)
BR (1) BR0314700A (ja)
CA (1) CA2499817A1 (ja)
NO (1) NO20051932L (ja)
RU (1) RU2005112247A (ja)
WO (1) WO2004029068A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434927A (zh) * 2014-12-16 2015-03-25 吉林农业大学 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用
CN104530167A (zh) * 2014-12-16 2015-04-22 吉林农业大学 水杨酸环戊烷并多氢菲酯a及其提取方法和药物用途
CN111053741A (zh) * 2019-12-31 2020-04-24 江苏省中医院 一种用于治疗炎症性肠病的基于β-谷甾醇与5-ASA的口服多敏感胶束前药
CN114014905A (zh) * 2021-12-03 2022-02-08 浙江科技学院 靶向PPARγ的甘草次酸类衍生物及其制备方法和用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
DE102004008035A1 (de) * 2004-02-19 2005-09-08 Symrise Gmbh & Co. Kg Verwendung von (2-Hydroxyphenyl)-alkoholen sowie diese Verbindungen enthaltende kosmetische oder therapeutische Formulierungen
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
DK2662382T3 (en) * 2012-05-10 2016-06-27 Beta Innov Sterol, MANUFACTURING METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE THEREOF FOR THE TREATMENT OF MULTIPLE glioblastoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518221A1 (de) * 1995-05-10 1996-11-14 Schering Ag Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen
CA2346881A1 (en) * 1998-07-20 2000-02-03 Egon Novak Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3 fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders
DE60017128T2 (de) * 1999-06-21 2006-01-26 Forbes Medi-Tech Inc., Vancouver Aromatische und heterocyclische Denvate von Phytosterolen und/oder Phytostano- len zur Behandlung von Gefässkrankheiten
KR100711861B1 (ko) * 1999-06-23 2007-04-25 포비스 메디-테크 인코포레이티드 심혈관질환을 치료하거나 예방하기 위한 피토스테롤 또는 피토스타놀과 아스코르브산의 결합체 및 그 용도
AU2001242130A1 (en) * 2000-03-07 2001-09-17 Forbes Medi-Tech Inc. Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
JP2004511573A (ja) * 2000-10-25 2004-04-15 フォーブス　メディ−テック　インコーポレーテッド フィトステロール及び／又はフィトスタノール及びアスコルビン酸を含む新規構造体並びに体重調節剤としてのその使用
PL371436A1 (en) * 2002-01-30 2005-06-13 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434927A (zh) * 2014-12-16 2015-03-25 吉林农业大学 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用
CN104530167A (zh) * 2014-12-16 2015-04-22 吉林农业大学 水杨酸环戊烷并多氢菲酯a及其提取方法和药物用途
CN104530167B (zh) * 2014-12-16 2016-02-24 吉林农业大学 水杨酸环戊烷并多氢菲酯a及其提取方法和药物用途
CN111053741A (zh) * 2019-12-31 2020-04-24 江苏省中医院 一种用于治疗炎症性肠病的基于β-谷甾醇与5-ASA的口服多敏感胶束前药
CN111053741B (zh) * 2019-12-31 2021-09-28 江苏省中医院 一种用于治疗炎症性肠病的基于β-谷甾醇与5-ASA的口服多敏感胶束前药
CN114014905A (zh) * 2021-12-03 2022-02-08 浙江科技学院 靶向PPARγ的甘草次酸类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
RU2005112247A (ru) 2006-01-20
AU2003266885A1 (en) 2004-04-19
BR0314700A (pt) 2005-07-26
NO20051932L (no) 2005-04-20
WO2004029068A1 (en) 2004-04-08
EP1556406A1 (en) 2005-07-27
KR20050084572A (ko) 2005-08-26
JP2006503840A (ja) 2006-02-02
CA2499817A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
CN1237071C (zh) 植物甾醇或植物甾烷醇的抗坏血酸衍生物及其组合物、食品和用途
CN1832957A (zh) 包含甾醇和/或甾烷醇及胆固醇生物合成抑制剂的新化合物和组合物 ,以及它们在治疗或预防多种疾病和症状中的用途
CN1244281C (zh) 包含食用油或脂肪和基本上溶于其中的植物甾醇和/或植物甾烷醇的组合物
CN1057768C (zh) 由木浆皂得到的甾醇组合物
CN1684971A (zh) 包括甾醇和 /或甾烷醇的新结构和组合物 ,以及特殊类别的抗炎药和其治疗或预防心血管病及其潜伏状况的用途 ,包括治疗高脂血症和其它以炎症为部分病因或症状的病症
CN101039585A (zh) 用于治疗医学疾病的植物甾醇酯和1,3－甘油二酯的混合物
AU6065599A (en) Phytosterol and/or phytostanol derivatives
CN1094042A (zh) 关于苯并噻吩类的改进
JP2002502879A (ja) 血清コレステロールレベルを減少させる合成物
JP3924310B2 (ja) 高血糖改善のための医薬及び飲食品
US7947669B2 (en) Agent for improving insulin resistance
WO2000015201A2 (en) Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders
CN1105362A (zh) 降低血清胆固醇的方法
CN1370179A (zh) 用于治疗或预防心血管疾病的植物甾醇和/或植物甾烷醇的芳族和杂环衍生物
CN1649607A (zh) 一种从黑稻中提取花色素苷的方法及其组合物
JPWO2005094838A1 (ja) 高血糖改善のための医薬及び飲食品
CN1226290C (zh) 新颖的核受体配体
US5270335A (en) Method of inhibiting metabolism of cholesterol
CN1511189A (zh) 制备富含非母育酚型高溶点不皂化物的植物油级分的方法
CN101233145B (zh) 改善胰岛素抵抗的药剂
WO2003090547A1 (en) A composition comprising waxy acids for effecting serum cholesterol levels
CN1505618A (zh) 二聚体异黄酮类
CA2346881A1 (en) Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3 fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders
WO2001066560A2 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
CN1293882C (zh) 具有降低血清胆固醇作用的复方植物甾醇及其制备工艺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication